Top

Published in:

Open Access 01-12-2011 | Review

Treatment of colorectal liver metastases

Author: Nabil Ismaili

Published in: World Journal of Surgical Oncology | Issue 1/2011

Abstract

Colorectal cancer (CRC) is the third most common cancer in the word. Liver metastasis is the most common site of colorectal metastases. The prognosis of resectable colorectal liver metastases (CRLM) was improved in the recent years with the consideration of chemotherapy and surgical resection as part of the multidisciplinary management of the disease; the current 5-year survival rates after resection of liver metastases are 25% to 40%. Resectable synchronous or metachronous liver metastases should be treated with perioperative chemotherapy based on three months of FOLFOX4 (5-fluorouracil [5FU], folinic acid [LV], and oxaliplatin) chemotherapy before surgery and three months after surgery. In the case of primary surgery, pseudo-adjuvant chemotherapy for 6 months, based on 5FU/LV, FOLFOX4, XELOX (capecitabine and oxaliplatin) or FOLFIRI (5FU/LV and irinotecan), should be indicated. In potentially resectable disease, primary chemotherapy based on more intensive regimens such as FOLFIRINOX (5FU/LV, irinotecan and oxaliplatin) should be considered to enhance the chance of cure. The palliative chemotherapy based on FOLFIRI, or FOLFOX4/XELOX with or without targeted therapies, is the mainstay treatment of unresectable disease. This review would provide additional insight into the problem of optimal integration of chemotherapy and surgery in the management of CRLM.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed

Adam R: Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003, 14 (Suppl 2): ii13-6.PubMed

Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P, European Colorectal Metastases Treatment Group: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006, 42 (14): 2212-21. 10.1016/j.ejca.2006.04.012.CrossRefPubMed

Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002, 235 (6): 759-66. 10.1097/00000658-200206000-00002.PubMedCentralCrossRefPubMed

Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF: Liver resection for colorectal metastases. J Clin Oncol. 1997, 15 (3): 938-46.PubMed

Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg. 1995, 19 (1): 59-71. 10.1007/BF00316981.CrossRefPubMed

Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, Faivre J: Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg. 1995, 82 (10): 1397-400. 10.1002/bjs.1800821034.CrossRefPubMed

Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G, European Colorectal Metastases Treatment Group: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European ColorectalMetastases Treatment Group. Eur J Cancer. 2007, 43 (14): 2037-45. 10.1016/j.ejca.2007.07.017. Epub 2007 Sep 4CrossRefPubMed

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008, 371 (9617): 1007-16. 10.1016/S0140-6736(08)60455-9.PubMedCentralCrossRefPubMed

10.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004, 240 (4): 644-57. discussion 657-8PubMedCentralPubMed

11.

Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull AD, Sullivan D, Stockman J, Blumgart LH, Fong Y: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999, 341 (27): 2039-48. 10.1056/NEJM199912303412702.CrossRefPubMed

12.

Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Sigurdson ER, O'Dwyer PJ, Benson AB: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol. 2002, 20 (6): 1499-505. 10.1200/JCO.20.6.1499.CrossRefPubMed

13.

Kemeny NE, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med. 2005, 352 (7): 734-5. 10.1056/NEJM200502173520723.CrossRefPubMed

14.

Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993, 306 (6880): 752-5. 10.1136/bmj.306.6880.752.PubMedCentralCrossRefPubMed

15.

Mayer RJ: Moving beyond fluorouracil for colorectal cancer. N Engl J Med. 2000, 343 (13): 963-4. 10.1056/NEJM200009283431309.CrossRefPubMed

16.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000, 343 (13): 905-14. 10.1056/NEJM200009283431302.CrossRefPubMed

17.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000, 18 (16): 2938-47.PubMed

18.

Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000, 18 (1): 136-47.PubMed

19.

Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004, 22 (2): 229-37.CrossRefPubMed

20.

Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004, 22 (7): 1209-14. 10.1200/JCO.2004.11.037.CrossRefPubMed

21.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007, 25 (13): 1670-6. 10.1200/JCO.2006.09.0928.CrossRefPubMed

22.

Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006, 94 (6): 798-805. 10.1038/sj.bjc.6603011.PubMedCentralCrossRefPubMed

23.

Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G: A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis. 2011, 13 (8): 846-52. 10.1111/j.1463-1318.2010.02206.x.CrossRefPubMed

24.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350 (23): 2335-42. 10.1056/NEJMoa032691.CrossRefPubMed

25.

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007, 25 (30): 4779-86. 10.1200/JCO.2007.11.3357.CrossRefPubMed

26.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008, 26 (12): 2013-9. 10.1200/JCO.2007.14.9930.CrossRefPubMed

27.

Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D, First BEAT investigators: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009, 20 (11): 1842-7. 10.1093/annonc/mdp233.CrossRefPubMed

28.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009, 360 (14): 1408-17. 10.1056/NEJMoa0805019.CrossRefPubMed

29.

Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009, 27 (5): 663-71. 10.1200/JCO.2008.20.8397.CrossRefPubMed

30.

Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996, 77 (7): 1254-62. 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I.CrossRefPubMed

31.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999, 230 (3): 309-18. 10.1097/00000658-199909000-00004. discussion 318-21PubMedCentralCrossRefPubMed

32.

http://thesaurus-cancerologie.snfge.org/data/ModuleDocument/publication/5/pdf/tmp960.html?abcpdf=20%2F07%2F2010+11%3A56%3A00#1377

33.

Chiche L, ANAES: When is first-line resection of hepatic metastasis indicated?. Gastroenterol Clin Biol. 2003, 27 Spec No 2:B11-3, B41-61

34.

Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M, Kahan JP: OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005, 23 (28): 7125-34. 10.1200/JCO.2005.08.722.CrossRefPubMed

35.

Rivoire M, De Cian F, Meeus P, Négrier S, Sebban H, Kaemmerlen P: Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002, 95 (11): 2283-92. 10.1002/cncr.10973.CrossRefPubMed

36.

Wein A, Riedel C, Köckerling F, Martus P, Baum U, Brueckl WM, Reck T, Ott R, Hänsler J, Bernatik T, Becker D, Schneider T, Hohenberger W, Hahn EG: Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol. 2001, 12 (12): 1721-7. 10.1023/A:1013521430755.CrossRefPubMed

37.

Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004, 15 (6): 933-9. 10.1093/annonc/mdh217.CrossRefPubMed

38.

Cals L, Rixe O, François E, Favre R, Merad L, Deplanque G, Laadem A, Juin P, Bereder JM, Bernardini D, Herait P: Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol. 2004, 15 (7): 1018-24. 10.1093/annonc/mdh259.CrossRefPubMed

39.

Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak O, Nordlinger B, European Organisation for Research and Treatment of Cancer Gastrointestinal Group: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005, 23 (22): 4856-65. 10.1200/JCO.2005.05.546.CrossRefPubMed

40.

Ho WM, Ma B, Mok T, Yeo W, Lai P, Lim R, Koh J, Wong YY, King A, Leow CK, Chan AT: Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Ann Oncol. 2005, 16 (5): 762-6. 10.1093/annonc/mdi154.CrossRef

41.

Seium Y, Stupp R, Ruhstaller T, Gervaz P, Mentha G, Philippe M, Allal A, Trembleau C, Bauer J, Morant R, Roth AD: Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol. 2005, 16 (5): 762-6. 10.1093/annonc/mdi154.CrossRefPubMed

42.

Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005, 23 (36): 9243-9. 10.1200/JCO.2005.07.740.CrossRefPubMed

43.

Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A: Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006, 13 (1): 58-65. 10.1245/ASO.2006.03.094.CrossRefPubMed

44.

Rivoire M, Thezenas S, Rebischung C, Viret F, Guimbaud R, Francois E, Ducreux M, Quenet F, Desseigne F, Ychou M: Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP). J Clin Oncol. 2008, 26: (May 20 suppl; abstr 4075)

45.

Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quénet F, Portier G, Nordlinger B: Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008, 62 (2): 195-201. 10.1007/s00280-007-0588-3.CrossRefPubMed

46.

Skof E, Rebersek M, Hlebanja Z, Ocvirk J: Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients withunresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer. 2009, 9: 120-10.1186/1471-2407-9-120.PubMedCentralCrossRefPubMed

47.

Zhao R, Zhu J, Ji X, Cai J, Wan F, Li Q, Zhong B, Tucker S, Wang D: A phase II study of irinotecan and capecitabine for patients withunresectable liver only metastases from colorectal cancer. Jpn J Clin Oncol. 2010, 40 (1): 10-6. 10.1093/jjco/hyp114.CrossRefPubMed

48.

Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A: Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol. 2005, 23 (3): 502-9.CrossRefPubMed

49.

Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008, 26 (11): 1830-5. 10.1200/JCO.2007.13.7679.CrossRefPubMed

50.

Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I: A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011, 22 (9): 2042-8. 10.1093/annonc/mdq714.CrossRefPubMed

51.

Shimada M, Nishioka M, Hanaoka J, Mori H, Ikemoto T, Imura S, Morine Y, Utsunomiya T: Impact of FOLFOXIRI plus bevacizumab on resectability and survival in patients with initially unresectable liver metastases from colorectal cancer. J Clin Oncol. 2011, 29: (suppl 4; abstr 621)

52.

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH: Tumour response and secondary resectability of colorectal livermetastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010, 11 (1): 38-47. 10.1016/S1470-2045(09)70330-4.CrossRefPubMed

53.

http://www.clinicaltrial.gov/ct2/show/NCT00438737?term=EORTC-40051&rank=1

54.

http://www.clinicaltrial.gov/ct2/show/NCT00482222?term=resectable+liver+metastasis+colorectal+cancer&rank=5

55.

André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004, 350 (23): 2343-51. 10.1056/NEJMoa032709.CrossRefPubMed

56.

Langer B, Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S, Tu D, Sargeant AM, Fields A: Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial Proc Am Soc Clin Oncol 21. 2002, (abstr 592)

57.

Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006, 24 (31): 4976-82. 10.1200/JCO.2006.06.8353.CrossRefPubMed

58.

Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008, 26 (30): 4906-11. 10.1200/JCO.2008.17.3781.CrossRefPubMed

59.

Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009, 20 (12): 1964-70. 10.1093/annonc/mdp236.CrossRefPubMed

60.

Voest EE, Snoeren N, Schouten SB, Bergman AM, van Werkhoven E, Loosveld OJL, van Gulik TM, Smit JM, Cats A, Boven E, Hesselink E, Rijken A, Tol M, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp J, Borel Rinkes I, van Hillegersberg R: A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. J Clin Oncol. 2011, 29: 2011-10.1200/JCO.2010.33.5091. (suppl; abstr 3565)CrossRef

61.

Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007, 94 (3): 274-86. 10.1002/bjs.5719.CrossRefPubMed

62.

Hübscher SG: Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006, 49 (5): 450-65. 10.1111/j.1365-2559.2006.02416.x.CrossRefPubMed

63.

Cleary JM, Tanabe KT, Lauwers GY, Zhu AX: Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist. 2009, 14 (11): 1095-105. 10.1634/theoncologist.2009-0152.CrossRefPubMed

64.

Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006, 43 (2 Suppl 1): S99-S112.CrossRefPubMed

65.

Ong JP, Younossi ZM: Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007, 11 (1): 1-16. 10.1016/j.cld.2007.02.009. viiCrossRefPubMed

66.

Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000, 132 (2): 112-7.CrossRefPubMed

67.

Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, Jarnagin WR: Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003, 7 (8): 1034-44. 10.1016/j.gassur.2003.09.012.CrossRefPubMed

68.

Veteläinen R, van Vliet A, Gouma DJ, van Gulik TM: Steatosis as a risk factor in liver surgery. Ann Surg. 2007, 245 (1): 20-30. 10.1097/01.sla.0000225113.88433.cf.PubMedCentralCrossRefPubMed

69.

Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006, 24 (13): 2065-72. 10.1200/JCO.2005.05.3074.CrossRefPubMed

70.

Helmy A: Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther. 2006, 23 (1): 11-25. 10.1111/j.1365-2036.2006.02742.x.CrossRefPubMed

71.

Valla DC: Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome. Gut. 2008, 7 (10): 1469-78.CrossRef

72.

Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006, 24 (31): 4983-90. 10.1200/JCO.2006.05.8156.CrossRefPubMed

73.

Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK: Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998, 77 (11): 2008-11. 10.1038/bjc.1998.333.PubMedCentralCrossRefPubMed

74.

Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004, 15 (3): 460-6. 10.1093/annonc/mdh095.CrossRefPubMed

75.

Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005, 200 (6): 845-53. 10.1016/j.jamcollsurg.2005.01.024.CrossRefPubMed

76.

Ellis LM, Curley SA, Grothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005, 23 (22): 4853-5. 10.1200/JCO.2005.23.754.CrossRefPubMed

77.

Natarajan A, Wagner B, Sibilia M: The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA. 2007, 104 (43): 17081-6. 10.1073/pnas.0704126104.PubMedCentralCrossRefPubMed

78.

Van Buren G 2nd, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, Fan F, Somcio R, Wu Y, Hicklin DJ, Ellis LM: Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol. 2008, 26 (11): 1836-42. 10.1200/JCO.2007.11.6566.CrossRefPubMed

79.

Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006, 243 (1): 1-7. 10.1097/01.sla.0000193603.26265.c3.PubMedCentralCrossRefPubMed

80.

Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M, European Colorectal Metastases Treatment Group: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Sixth International Colorectal Liver Metastases Workshop. Ann Oncol. 2009, 20 (6): 985-92. 10.1093/annonc/mdn735.CrossRefPubMed

Title: Treatment of colorectal liver metastases
Author: Nabil Ismaili
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2011
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-9-154

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of colorectal liver metastases

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: A retrospective study of single institution

Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer

Risk factors of gallbladder cancer in Karachi-a case-control study

Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients

Intra-ocular melanoma metastatic to an axillary lymph node: A case report

Lymphoma of the breast: A mimic of inflammatory breast cancer